Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval

Company Has Initiated FINRA Process to Complete Rebranding and Ticker Update

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bionoid Pharma, Inc. (OTC PINK:BINP) (“Bionoid” or the “Company”) is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company’s formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets.

Subject to FINRA’s approval, the name and symbol change will be reflected in market listings and all future communications. This step marks the continued execution of the Company’s new strategic direction, which centers on leveraging artificial intelligence to acquire, integrate, and grow technology-driven businesses.

“This milestone moves us one step closer to fully implementing the AI Maverick vision,” said Wayne Cockburn, CEO. “As we align our public identity with our operational focus, we’re unlocking new opportunities to scale our platform and partner with innovators across AI, biotech, and digital health. Our shareholders can expect a bold, tech-forward approach to growth.”

About AI Maverick Intel, Inc.

AI Maverick Intel, Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. AI Maverick Intel aims to deliver long-term value through innovation, efficiency, and strategic partnerships.

Stay Connected:

Website | AI Maverick | OTC:BINP | X: @BionoidPharminc

Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com

SOURCE: AI Maverick Intel, Inc.

View the original press release on ACCESS Newswire

Staff

Recent Posts

Leostream Announces Unified HPC Remote Access Interoperability to Simplify Decentralized Live and Post-Production

Partner ecosystem built with technical integrations and validation from Nutanix, AWS, Red Hat OpenShift, HP,…

3 hours ago

Introducing the 2026 McGraw Hill Pathfinder Award Winners

National award program recognizes innovative educators across preK-12, higher ed and post-graduate educationCOLUMBUS, Ohio--(BUSINESS WIRE)--Three…

3 hours ago

RADIESSE(R) Receives FDA Approval for Décolleté Wrinkles as Dr. Rubinstein Provides Proven, FDA-Approved Solutions in New York and New Jersey

Double board-certified facial plastic surgeon offers RADIESSE treatments at Laser & Cosmetic Surgery Specialists in…

9 hours ago

AMC Health Appoints Sol Babani and Symbiosis Advisors as Strategic Advisor to Its Decentralized Clinical Trial Service Line

Industry veteran brings deep CRO and biopharma expertise from ICON, PRA Health Sciences, and Covance…

9 hours ago

GrammaTech Research Featured Across Talks and Demos at HCSS

ITHACA, NY / ACCESS Newswire / May 5, 2026 / GrammaTech will present four research…

9 hours ago

Unusual Machines Initiates $75M in Strategic Materials Purchases to Support Program-Driven Demand

Purchase orders position the Company to expand production and enable compliant, U.S.-based supply at scale…

9 hours ago